Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Cancer Genomics & Proteomics
    • Anticancer Research
    • In Vivo

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Genomics & Proteomics
  • Other Publications
    • Cancer Genomics & Proteomics
    • Anticancer Research
    • In Vivo
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Cancer Genomics & Proteomics

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Visit iiar on Facebook
  • Follow us on Linkedin

nilotinib

  • Open Access
    Expression Patterns of CD44 and AREG Under Treatment With Selective Tyrosine Kinase Inhibitors in HPV+ and HPV− Squamous Cell Carcinoma
    BENJAMIN KANSY, CHRISTOPH ADERHOLD, LENA HUBER, SONJA LUDWIG, RICHARD BIRK, ANNE LAMMERT, STEPHAN LANG, NICOLE ROTTER and BENEDIKT KRAMER
    Cancer Genomics & Proteomics September 2020, 17 (5) 579-585; DOI: https://doi.org/10.21873/cgp.20214
  • Open Access
    HIF-1α and mTOR – Possible Novel Strategies of Targeted Therapies in p16-positive and -negative HNSCC
    BENEDIKT KRAMER, MAX POLIT, RICHARD BIRK, NICOLE ROTTER and CHRISTOPH ADERHOLD
    Cancer Genomics & Proteomics May 2018, 15 (3) 175-184;
Cancer & Genome Proteomics

© 2026 Cancer Genomics & Proteomics

Powered by HighWire